{"id":23481,"date":"2022-12-20T21:37:00","date_gmt":"2022-12-20T13:37:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23481"},"modified":"2025-01-27T21:50:11","modified_gmt":"2025-01-27T13:50:11","slug":"prenetics-acquires-majority-stake-in-act-genomics-to-boost-oncology-services","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23481","title":{"rendered":"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services"},"content":{"rendered":"\n<p>Hong Kong-based Prenetics Global Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/PRE:NASDAQ\">NASDAQ: PRE<\/a>) has announced the acquisition of a majority stake in Taiwan-based ACT Genomics Holdings Co., Ltd, aiming to establish a powerhouse Asia-based genomics and precision oncology firm. The transaction involves a USD 20 million cash payment and the issuance of 19.9 million common Prenetics shares (estimated by <a href=\"https:\/\/flcube.com\/\">Fineline Info &amp; Tech<\/a> to be worth approximately USD 42 million at the time of the deal announcement).<\/p>\n\n\n\n<p><strong>ACT Genomics Profile and Services<\/strong><br>ACT operates from Taipei, with sites in Hong Kong, Singapore, Tokyo, Bangkok, and the United Kingdom. The firm offers Next-Generation Sequencing (NGS), CAP-accredited laboratories, bioinformatics, and proprietary AI algorithms. Its services include optimal cancer treatment planning, immunotherapy evaluation, cancer relapse and drug resistance monitoring, and cancer risk assessment services to medical professionals.<\/p>\n\n\n\n<p><strong>Prenetics Profile and Services<\/strong><br>Prenetics, meanwhile, operates in the United Kingdom, India, South Africa, and Southeast Asia in addition to Hong Kong. The firm offers consumer genetic testing and early colorectal cancer screening, as well as COVID-19 testing, rapid point of care and at-home diagnostic testing, alongside a medical genetic testing service.<\/p>\n\n\n\n<p><strong>Future Prospects and Strategic Implications<\/strong><br>The aim of the acquisition is to provide a full range of cancer molecular diagnostics for the 9 million + cancer patients diagnosed in Asia each year. ACT is expected to immediately begin contributing USD 25-30 million in revenues during 2023. This strategic move positions Prenetics to further expand its presence in the genomics and precision oncology market, addressing significant unmet medical needs and improving patient outcomes through advanced diagnostic solutions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[10],"tags":[3342,1377,1378],"class_list":["post-23481","post","type-post","status-publish","format-standard","hentry","category-deals","tag-act-genomics","tag-nasdaq-pre","tag-prenetics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake in Taiwan-based ACT Genomics Holdings Co., Ltd, aiming to establish a powerhouse Asia-based genomics and precision oncology firm. The transaction involves a USD 20 million cash payment and the issuance of 19.9 million common Prenetics shares (estimated by Fineline Info &amp; Tech to be worth approximately USD 42 million at the time of the deal announcement).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23481\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23481\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-20T13:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-27T13:50:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23481#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23481\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services\",\"datePublished\":\"2022-12-20T13:37:00+00:00\",\"dateModified\":\"2025-01-27T13:50:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23481\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ACT Genomics\",\"NASDAQ: PRE\",\"Prenetics\"],\"articleSection\":[\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23481#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23481\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23481\",\"name\":\"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-20T13:37:00+00:00\",\"dateModified\":\"2025-01-27T13:50:11+00:00\",\"description\":\"Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake in Taiwan-based ACT Genomics Holdings Co., Ltd, aiming to establish a powerhouse Asia-based genomics and precision oncology firm. The transaction involves a USD 20 million cash payment and the issuance of 19.9 million common Prenetics shares (estimated by Fineline Info & Tech to be worth approximately USD 42 million at the time of the deal announcement).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23481#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23481\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23481#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services - Insight, China&#039;s Pharmaceutical Industry","description":"Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake in Taiwan-based ACT Genomics Holdings Co., Ltd, aiming to establish a powerhouse Asia-based genomics and precision oncology firm. The transaction involves a USD 20 million cash payment and the issuance of 19.9 million common Prenetics shares (estimated by Fineline Info & Tech to be worth approximately USD 42 million at the time of the deal announcement).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23481","og_locale":"en_US","og_type":"article","og_title":"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23481","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-20T13:37:00+00:00","article_modified_time":"2025-01-27T13:50:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23481#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23481"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services","datePublished":"2022-12-20T13:37:00+00:00","dateModified":"2025-01-27T13:50:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23481"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ACT Genomics","NASDAQ: PRE","Prenetics"],"articleSection":["Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23481#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23481","url":"https:\/\/flcube.com\/?p=23481","name":"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-20T13:37:00+00:00","dateModified":"2025-01-27T13:50:11+00:00","description":"Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake in Taiwan-based ACT Genomics Holdings Co., Ltd, aiming to establish a powerhouse Asia-based genomics and precision oncology firm. The transaction involves a USD 20 million cash payment and the issuance of 19.9 million common Prenetics shares (estimated by Fineline Info & Tech to be worth approximately USD 42 million at the time of the deal announcement).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23481#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23481"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23481#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23481"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23481\/revisions"}],"predecessor-version":[{"id":23484,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23481\/revisions\/23484"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}